# DUTRENEO (NCT03472274)

> Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)

No report yet. It can be ordered.

- Drugs tested: durvalumab plus tremelimumab

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03472274
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Fundacion CRIS de Investigación para Vencer el Cáncer
- Conditions: Bladder Cancer
- Interventions: Durvalumab; Tremelimumab; Cisplatin-based neoadjuvant chemotherapy
- Enrollment: 101
- Primary outcome: Antitumor activity

## Indexed commentary on DUTRENEO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 33 posts on X
- 1 YouTube video
- 1 video on X

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=dutreneo-nct03472274

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03472274", "email": "<work email>"}; the inbox owner confirms by the emailed link.